Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates a steady flow of news across diagnostics, medical devices, nutritionals and branded generic medicines, reflecting its role as a global healthcare company serving people in more than 160 countries. News coverage on this page highlights regulatory milestones, product launches, clinical data, corporate actions and community initiatives that shape Abbott’s business and its impact on patients.
Recent announcements include FDA approvals and clearances for cardiovascular and structural heart technologies, such as the Volt PFA System for treating atrial fibrillation and the Amplatzer Piccolo Delivery System for minimally invasive closure of patent ductus arteriosus in premature infants. Abbott also reports developments in diabetes care and metabolic health, including enhancements to its Libre app through the Libre Assist feature, which uses generative AI and continuous glucose monitoring data to help people living with diabetes understand how food choices may affect glucose levels, and the expansion of its Lingo over-the-counter continuous glucose monitor to additional mobile platforms.
Investors and observers will also find news about Abbott’s nutrition business, such as new Ensure Max Protein shakes aimed at supporting muscle health for active and older adults, as well as information on public health partnerships and community programs like the "We Give Blood" competition with the Big Ten Conference and the HeartMates community for people with heart health challenges. Corporate updates include dividend declarations and increases, as well as the announced Agreement and Plan of Merger to acquire Exact Sciences Corporation, which would expand Abbott’s presence in cancer screening and precision oncology diagnostics.
This news feed provides a centralized view of Abbott’s latest announcements, allowing readers to follow developments in its key business segments and understand how new products, regulatory events and strategic transactions may influence the company over time.
Abbott has become the first anchor sponsor of the American Diabetes Association's Health Equity Now initiative, committing $5 million over three years. This platform aims to address health disparities faced by underserved diabetes populations. Data highlights that the risk of diabetes is significantly higher among Black Americans (77%) and Latinos (66%). Abbott will support advocacy efforts to enhance access to medical technologies and foster community engagement programs to improve health outcomes among these communities.
Summary not available.
Abbott has launched the IonicRF™ Generator, a radiofrequency ablation device cleared by the FDA for non-surgical pain management targeting the nervous system. This is Abbott's first radiofrequency device, approved in both the U.S. and Europe. Designed to provide a tailored approach for pain relief, studies indicate the therapy can offer relief for 6-12 months. This launch helps expand Abbott's neuromodulation portfolio aimed at patients seeking alternatives to surgery and opioids.
Summary not available.
Abbott reported third-quarter 2020 sales of $8.9 billion, reflecting a 9.6% increase from the previous year. Diluted EPS was $0.69 GAAP and $0.98 adjusted, marking a 16.7% growth. Abbott expects full-year GAAP EPS of at least $2.35 and adjusted EPS of $3.55. Notable developments include FDA Emergency Use Authorization for the BinaxNOW COVID-19 test and the launch of FreeStyle Libre 2. The company maintains a strong dividend history, recently declaring its 387th consecutive quarterly dividend.
Researchers from Abbott, the University of Illinois, and the U.S. Air Force have discovered a strong connection between physical fitness, cognitive performance, and optimal nutrition. In a 12-week study involving 148 U.S. Air Force personnel, participants receiving a high-protein nutritional drink exhibited improvements including an 11% boost in working memory and a 6% enhancement in reaction time. Additionally, muscle mass increased by over two pounds, and resting heart rate dropped by 8%. Abbott aims to develop future nutritional products based on these findings.
Abbott (NYSE: ABT) has received Emergency Use Authorization (EUA) from the FDA for its AdviseDx SARS-CoV-2 IgM lab-based serology test. This test, available on ARCHITECT and Alinity platforms, detects IgM antibodies to indicate recent or prior COVID-19 infections. Abbott has developed seven tests for COVID-19 since the pandemic began, including molecular and rapid antigen tests. The new test demonstrates high reliability with 99.56% specificity and 95.00% sensitivity, aiding healthcare providers in assessing patient recovery.
Abbott has released interim clinical data on its ID NOW COVID-19 rapid test, confirming previous FDA submissions for Emergency Use Authorization. The study involved 1,003 participants and demonstrated an overall performance of 93.3% positive agreement and 98.4% negative agreement to lab-based PCR tests. High-performance metrics were noted, particularly in symptomatic patients within seven days post-symptom onset. The study reaffirms the critical role of rapid testing in pandemic management, positioning ID NOW as a reliable tool for identifying COVID-19 infections.
Abbott (NYSE: ABT) has received CE Mark approval for its FreeStyle Libre 3 system, enabling its use for diabetes management in Europe. This next-generation glucose monitoring system offers real-time glucose readings every minute via a smartphone, boasting a 14-day accuracy in a compact design. The FreeStyle Libre 3 sensor, priced similarly to previous models, aims to enhance accessibility while reducing environmental impact with a significant decrease in plastic and carton use. This system is expected to continue Abbott's legacy of improving diabetes care and reducing healthcare costs.
Abbott (NYSE: ABT) has received CE Mark approval for its fourth-generation MitraClip™ Transcatheter Mitral Valve Repair System, enhancing treatment options for mitral regurgitation (MR) in Europe. The MitraClip G4 improves upon previous models with advanced steering, a variety of clip sizes, and independently controlled grippers. This system, already approved in the U.S., offers a less invasive alternative to open-heart surgery for patients unable to undergo conventional procedures. Notably, over 100,000 patients have been treated globally, showcasing its clinical success and impact on patient outcomes.